271 related articles for article (PubMed ID: 23766489)
21. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
22. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
Keirns J; Sawamoto T; Holum M; Buell D; Wisemandle W; Alak A
Antimicrob Agents Chemother; 2007 Feb; 51(2):787-90. PubMed ID: 17116670
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
Liu P; Foster G; LaBadie RR; Gutierrez MJ; Sharma A
J Clin Pharmacol; 2008 Jan; 48(1):73-84. PubMed ID: 18025525
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.
Chan HM; Duran SH; Walz PH; Ravis WR
J Vet Pharmacol Ther; 2009 Jun; 32(3):235-40. PubMed ID: 19646087
[TBL] [Abstract][Full Text] [Related]
25. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
27. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Purkins L; Wood N; Kleinermans D; Love ER
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of voriconazole after oral and intravenous administration to horses.
Davis JL; Salmon JH; Papich MG
Am J Vet Res; 2006 Jun; 67(6):1070-5. PubMed ID: 16740104
[TBL] [Abstract][Full Text] [Related]
29. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.
Purkins L; Wood N; Ghahramani P; Love ER; Eve MD; Fielding A
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):37-44. PubMed ID: 14616412
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses.
Clode AB; Davis JL; Salmon J; Michau TM; Gilger BC
Am J Vet Res; 2006 Feb; 67(2):296-301. PubMed ID: 16454636
[TBL] [Abstract][Full Text] [Related]
31. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
Walsh TJ; Karlsson MO; Driscoll T; Arguedas AG; Adamson P; Saez-Llorens X; Vora AJ; Arrieta AC; Blumer J; Lutsar I; Milligan P; Wood N
Antimicrob Agents Chemother; 2004 Jun; 48(6):2166-72. PubMed ID: 15155217
[TBL] [Abstract][Full Text] [Related]
34. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
[TBL] [Abstract][Full Text] [Related]
35. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.
Purkins L; Wood N; Kleinermans D; Greenhalgh K; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):17-23. PubMed ID: 14616409
[TBL] [Abstract][Full Text] [Related]
36. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.
Purkins L; Wood N; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):51-5. PubMed ID: 14616414
[TBL] [Abstract][Full Text] [Related]
37. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
38. [Level of evidence for therapeutic drug monitoring of voriconazole].
Hulin A; Dailly E; Le Guellec C;
Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos).
Kline Y; Clemons KV; Woods L; Stevens DA; Tell LA
Med Mycol; 2011 Jul; 49(5):500-12. PubMed ID: 21171838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]